Yao Liu, MD, MS

Yao Liu, MD, MS

Assistant Professor

As a clinician-scientist, Dr. Yao Liu leverages new technology to enhance our understanding and management of glaucoma, diabetic retinopathy, and other vision-threatening eye diseases using imaging, telemedicine, and clinical trials of new medications and surgical devices. Dr. Liu is the Director of the UW Teleophthalmology Program, which aims to prevent blindness by expanding access to innovative eye care.

Contact Administrative Assistant LEARN ABOUT THE LIU LAB

Specialties and Interests:
Adult and pediatric glaucoma, glaucoma and cataract surgery, anterior segment surgery, optic nerve imaging

  • Clinical trials of new medications and surgical devices
  • Telemedicine for diabetic eye screening
  • Macular pigment as a glaucoma risk factor
  • Clinical and surgical glaucoma management

Fellowship:
Glaucoma, University of California, Davis Eye Center, Sacramento, CA

Residency:
Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA

Internship:
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Medical School:
Harvard Medical School, Boston, MA

PUBLICATIONS

For the most up-to-date publication list for Dr. Yao Liu, click here.

GRANTS AND MONETARY AWARDS


Current 

Agency: NIH/NEI K23 EY026518
Title: Advancing Integration of Tele-ophthalmology for Diabetic Retinopathy in Rural, Multi-payer Settings
Role: Principal Investigator (Mentors: Maureen Smith, Ron Klein, Jane Mahoney)
Percent effort: 75%
Total amount: $811,485
Period: 4/01/16-3/31/21
This study develops an implementation package to facilitate adoption of telemedicine for diabetic retinopathy in rural healthcare settings. Training in health services research includes M.S. in Clinical Investigation. 

Agency: Wisconsin Public Service Commission
Title: Telemedicine Grant, Mile Bluff Medical Center
Role: Collaborator
Percent effort: N/A
Total amount: $55,600
Period: 5/01/18-4/30/19
This funding supports the purchase of 4 non-mydriatic fundus cameras for teleophthalmology at Mile Bluff Medical Center’s Outreach clinics. 

Agency: Lions Eye Bank of Wisconsin Gift of Sight Discovery Fund
Title: Macular Pigment as a Modifiable Glaucoma Risk Factor in Older women
Role: Principal Investigator
Percent effort: 5%
Total amount: $50,000
Period: 1/01/2019-12/31/2019
This is a glaucoma ancillary study to CAREDS2 (R01 EY025292) that will provide the first longitudinal evidence as to whether low macular pigment levels are associated with an increased risk of glaucoma. 

Agency: NIH/NEI R01 EY025292
Title: Macular Pigment in Aging and Disease (CAREDS2)
Role: Co-Investigator (Multiple PIs: Julie Mares, Barbara Blodi)
Percent effort: 5%
Total amount: $1,180,766
Period: 6/01/2015-5/31/2020
This study assesses the relationship between RNFL thickness on spectral domain OCT to macular pigment optical density and risk of macular degeneration in Carotenoids in Age-Related Eye Disease Study (CAREDS). 

Agency: CDC U01 DP006074 (University of Chicago NORC)
Title: Establish a Vision and Eye Health Surveillance System for the Nation
Role: Consultant (PI: David Rein)
Percent effort: N/A
Total amount: $25,000 (subaward)
Period: 10/01/2015-9/30/2019
The purpose of this research is to develop, test, and implement a vision and eye health surveillance system to provide population estimates of vision loss, eye diseases, health disparities, and access to eye care. 

Past Awards 

Agency: American Glaucoma Society Mentoring for Advancement of Physician-Scientists (MAPS) Award
Title: Macular Pigment and Glaucoma Incidence in the Carotenoids in Age-Related Eye Disease Study 2 (CAREDS2)
Role: Principal Investigator (Mentors: Julie Mares, Thasarat Vajaranant)
Percent effort: N/A
Total amount: $10,000
Period: 1/01/2018-12/31/2018
This is a glaucoma ancillary study to CAREDS2 (R01 EY025292) that will provide the first longitudinal evidence as to whether low macular pigment levels are associated with an increased incidence of glaucoma. 

Agency: Wisconsin Partnership Program New Investigator Program
Title: Advancing Tele-ophthalmology for Diabetic Retinopathy in Rural Wisconsin
Role: Principal Investigator
Percent effort: 5%
Total amount: $100,000
Period: 4/01/16-3/31/18
This study develops an implementation package to facilitate adoption of telemedicine for diabetic retinopathy in rural Wisconsin. 

Agency: NIH/NCATS UL1 TR002373 Univ. of WI ICTR Basic & Clinical Translational Research Pilot Award
Title: Macular Pigment as a Modifiable Glaucoma Risk Factor in Older women
Role: Principal Investigator
Percent effort: 5%
Total amount: $50,000
Period: 6/01/2016-1/31/2018
This is a glaucoma ancillary study to CAREDS2 (R01 EY025292) that will provide the first longitudinal evidence as to whether low macular pigment levels are associated with an increased risk of glaucoma. 

Agency: American Glaucoma Society Mentoring for Advancement of Physician-Scientists (MAPS) Award
Title: Macular pigment levels as a glaucoma risk factor in the Carotenoids in Age-Related Eye Disease Study 2
Role: Principal Investigator (Mentors: Julie Mares, Thasarat Vajaranant)
Percent effort: N/A
Total amount: $10,000
Period: 6/01/2016-5/31/2017
This is a glaucoma ancillary study to CAREDS2 (R01 EY025292) that will provide the first longitudinal evidence as to whether low macular pigment levels are associated with an increased risk of glaucoma. 

Agency: Frederick A. Davis Funds, University of Wisconsin Dept. of Ophthalmology and Visual Sciences
Title: Pilot study to assess the results of multifocal electroretinography (mfERG) and multifocal visual evoked potentials (mfVEP) in patients with glaucoma.
Role: Principal Investigator
Percent effort: N/A
Total amount: $7,000
Period: 10/01/14 – 10/01/18
This study evaluates the use of multifocal electroretinograms and a novel multifocal visual evoked potentials algorithm as objective tests of visual function among patients with glaucoma. 

Agency: Aerie Pharmaceuticals
Title: Aerie Glaucoma Trial – PG324-CS301
Role: Principal Investigator (Site)
Percent effort: N/A
Total amount: $21,125
Period: 7/14/2015-12/31/2017
A randomized, multicenter study assessing the safety and efficacy of PG324 Ophthalmic Solution compared to AR-13324 and Latanoprost Ophthalmic Solution in subjects with elevated intraocular pressure. 

Agency: Bausch and Lomb Inc.
Title: Bausch and Lomb Glaucoma Trial – Protocol 770
Role: Principal Investigator (Site)
Percent effort: N/A
Total amount: $17,057
Period: 5/09/2013-6/1/2015
A randomized, multicenter study comparing the safety and efficacy of BOL-303259-X ophthalmic solution with timolol in subjects with open angle glaucoma or ocular hypertension.